loader from loading.io
Prostate Cancer — Microlearning Activity 1 with Dr Rana R McKay: ESMO Congress 2025 Review show art Prostate Cancer — Microlearning Activity 1 with Dr Rana R McKay: ESMO Congress 2025 Review

Research To Practice | Oncology Videos

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics: AKT inhibitors for PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (0:00) Radioligand-directed therapy for PSMA-positive metastatic hormone-sensitive prostate cancer (8:18) Radiation therapy in combination with enzalutamide for high-risk localized prostate cancer (13:14)

info_outline
HER2-Positive Gastrointestinal Cancers — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium show art HER2-Positive Gastrointestinal Cancers — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium

Research To Practice | Oncology Videos

Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics:  Introduction (0:00) Biliary Tract Cancers — Dr Ellis (1:56) Gastroesophageal Cancers — Dr Wainberg (24:27) Colorectal Cancer — Prof Van Cutsem (59:13)

info_outline
Endocrine-Based Therapy for HR-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series show art Endocrine-Based Therapy for HR-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series

Research To Practice | Oncology Videos

Featuring perspectives from Dr Angela DeMichele, Dr Komal Jhaveri, Dr Erica Mayer, Dr Hope S Rugo and Dr Seth Wander, including the following topics:  Introduction (0:00) 1985 NCI Consensus Conference on Early Breast Cancer: Sir Richard Peto, FRS (2:01) Current Role of Genomic Assays in Treatment Decision-Making for Localized Hormone Receptor (HR)-Positive Breast Cancer — Dr DeMichele (5:13) Case: A premenopausal woman in her mid 40s with an ER-positive, HER2-negative, node-negative infiltrating ductal carcinoma (IDC) after partial mastectomy/radiation therapy who enrolls in the...

info_outline
Metastatic Bladder Cancer — Rapid Case Review Issue 1 show art Metastatic Bladder Cancer — Rapid Case Review Issue 1

Research To Practice | Oncology Videos

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics: Case: A man in his early 60s with metastatic urothelial bladder cancer (mUBC) and medical history of tobacco use receives first-line enfortumab vedotin (EV) and pembrolizumab with excellent response after 3 cycles — Dr Fahey (0:00) Case: A woman in her early 80s with tumor mutational burden-high mUBC receives pembrolizumab with complete response and later discontinues after developing Grade 1 pneumonitis has no further evidence of disease...

info_outline
Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review show art Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review

Research To Practice | Oncology Videos

Featuring perspectives from Prof Michael Dickinson and Dr Laurie H Sehn, including the following topics:  Introduction (0:00) Future Treatment of Non-Hodgkin Lymphoma (NHL) (2:24) Case: A man in his mid 60s with diffuse large B-cell lymphoma (DLBCL) and early relapse on axicabtagene ciloleucel receives glofitamab — Dr Sehn (8:10) Case: A man in his late 60s with Type 2 diabetes, congestive heart failure and chronic obstructive pulmonary disease receives glofitamab monotherapy after glofitamab with gemcitabine/oxaliplatin for relapsed GCB-type double-hit DLBCL — Matthew Lunning, DO...

info_outline
Relapsed/Refractory Multiple Myeloma — ASH 2025 Review show art Relapsed/Refractory Multiple Myeloma — ASH 2025 Review

Research To Practice | Oncology Videos

Featuring perspectives from Dr Sagar Lonial and Dr María-Victoria Mateos, including the following topics:  Introduction (0:00) Best of ASH Multiple Myeloma (1:56) Case: A man in his late 50s with t(11;14) IgA kappa myeloma discovered during workup for new Stage IV kidney disease who has a chest wall plasmacytoma receives daratumumab with CyBorD and radiation therapy to the plasmacytoma with minimal response — Jeremy Lorber, MD (8:35) Antibody-Drug Conjugates and Other Emerging Novel Therapies for Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lonial (16:58) Case: A man in his...

info_outline
HER2-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series show art HER2-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series

Research To Practice | Oncology Videos

Featuring perspectives from Prof Giuseppe Curigliano, Prof Nadia Harbeck, Dr Ian E Krop, Dr Nancy U Lin and Dr Joyce O’Shaughnessy, including the following topics:  Introduction (0:00) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Prof Harbeck (1:39) Case: A woman in her mid 50s presents with locally advanced ER-positive, HER2-positive breast cancer — Alan B Astrow, MD (12:52) Case: A woman in her mid 40s with ER-positive, HER2-positive Stage II breast cancer s/p neoadjuvant TCHP with residual disease receives adjuvant T-DM1 but discontinues...

info_outline
Follicular Lymphoma and Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition show art Follicular Lymphoma and Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition

Research To Practice | Oncology Videos

Featuring perspectives from Dr Nancy L Bartlett, Dr John P Leonard, Dr Matthew Matasar, Dr Loretta J Nastoupil and Prof Pier Luigi Zinzani, including the following topics:  Introduction (0:00) Rational Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Matasar (1:34) Case: A man in his late 50s who presents with left testicular swelling and abdominal discomfort is diagnosed with ABC-subtype Stage IV DLBCL — Laurie H Sehn, MD, MPH (11:27) Clinical Utility of CD19-Directed Monoclonal Antibodies for DLBCL...

info_outline
Colorectal Cancer — 5-Minute Journal Club Issue 2 with Dr Scott Kopetz: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays show art Colorectal Cancer — 5-Minute Journal Club Issue 2 with Dr Scott Kopetz: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays

Research To Practice | Oncology Videos

Featuring an interview with Dr Scott Kopetz, including the following topics:  Circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy de-escalation in the treatment of Stage III colon cancer from the ctDNA-negative cohort of the DYNAMIC-III trial (0:00) Prognostic and predictive role of ctDNA in the management of Stage III colon cancer treated with celecoxib: Findings from the CALGB (Alliance)/SWOG 80702 trial (8:01) Phase III ALTAIR study comparing trifluridine/tipiracil to placebo for patients with molecular residual disease after curative resection of colorectal cancer (CRC); a...

info_outline
Myelofibrosis and Systemic Mastocytosis — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition show art Myelofibrosis and Systemic Mastocytosis — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition

Research To Practice | Oncology Videos

Featuring perspectives from Prof Claire Harrison, Dr Andrew T Kuykendall, Dr Stephen T Oh, Dr Jeanne Palmer and Dr Raajit K Rampal, including the following topics:  Introduction (0:00) Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Palmer (1:46) Case: A woman in her mid 70s presents with symptomatic JAK2 V61F-mutant primary MF with mild anemia and normal platelet count — John Mascarenhas, MD (16:09) Discussion: Asymptomatic MF; re-reads of pathology reports; “triple-negative” MF; secondary causes — Laura C Michaelis, MD (22:47)...

info_outline
 
More Episodes

Featuring an interview with Dr Priyanka Sharma, including the following topics:

  • Patient-reported outcomes from the SERENA-6 trial of camizestrant with a CDK4/6 inhibitor for patients with HR-positive, HER2-negative advanced breast cancer and ESR1 mutations emerging during first-line endocrine-based therapy (0:00)
    • Mayer E et al. Patient-reported outcomes (PROs) from the SERENA-6 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC). ESMO 2025;Abstract 486MO.
  • Imlunestrant and abemaciclib versus fulvestrant and abemaciclib for ER-positive, HER2-negative advanced breast cancer: An indirect treatment comparison of 3 Phase III trials (3:00)
    • Bidard FC et al. Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): An indirect treatment comparison (ITC) of three phase 3 trials. ESMO 2025;Abstract 496P .
  • Giredestrant in the treatment of ER-positive, HER2-negative breast cancer: The Phase III evERA Breast Cancer and EMPRESS trials (5:39)
    • Mayer E et al. Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial. ESMO 2025;Abstract LBA16.
    • Llombart-Cussac A et al. Preoperative window-of-opportunity study with giredestrant or tamoxifen (tam) in premenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) and Ki67≥10% early breast cancer (EBC): The EMPRESS study. ESMO 2025;Abstract 294MO.
  • Capivasertib/fulvestrant as first- and second-line endocrine-based therapy for PIK3CA/AKT1/PTEN-altered HR-positive advanced breast cancer in the CAPItello-291 trial and gedatolisib/fulvestrant with or without palbociclib for HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer in the VIKTORIA-1 trial.(10:25)
    • Rugo HS et al. Capivasertib plus fulvestrant as first and second-line endocrine-based therapy in PIK3CA/AKT1/PTEN-altered hormone receptor-positive advanced breast cancer: Subgroup analysis from the phase 3 CAPItello-291 trial. ESMO 2025;Abstract 526P.
    • Hurvitz SA et al. Gedatolisib (geda) + fulvestrant ± palbociclib (palbo) vs fulvestrant in patients (pts) with HR+/ HER2-/PIK3CA wild-type (WT) advanced breast cancer (ABC): First results from VIKTORIA-1. ESMO 2025;Abstract LBA17.

CME information and select publications